BACKGROUND In a previous study, the authors tested the combination of fotemustine (FM)
100 mg/m2 intravenously (iv) on Day 1, dacarbazine (DTIC) 250 mg/m2 iv on Days 2–5, and …

Forty-three consecutive patients with advanced melanoma not previously treated with
cytotoxic drugs (22 of them had already received adjuvant recombinant interferon alpha2a …

Purpose: Phase II and III studies have shown that the addition of interleukin-2 (IL-2) and
interferon alfa-2b (IFN-2b) in multiagent chemotherapy (CT) for advanced melanoma …

Fotemustine and dacarbazine constitute the most active single chemotherapeutic agents in
the treatment of melanoma. In this phase II study we evaluated the activity and toxicity of a …

BACKGROUND The objective of the current study was to evaluate the response rate,
survival, and toxicity of treatment with cisplatin and high dose intravenous continuous …

Background Based on phase II trial results, chemoimmunotherapy combinations have
become the preferred treatment for patients with metastatic melanoma in many institutions …

Background: Temozolomide (TMZ) is an oral alkylating agent; it produces DNA methyl
adducts, which are removed by the DNA repair enzyme AGAT. In vitro studies suggest that …

The efficacy and tolerability of fotemustine, cisplatin, α-interferon and interleukin-2
biochemotherapy were evaluated in advanced melanoma patients. The schedule consisted …

Despite the poor prognosis of metastatic malignant melanoma, polychemotherapy with
dacarbazine and fotemustine has shown promising results in several studies. We report on …

The purpose of this study was to compare the response rate, overall and 1-year survival in
patients with advanced melanoma treated with a standard therapy, dacarbazine and …